Entecavir, a drug for treating hepatitis B has achieved the official GMP certification by the health authorities of Cyprus and passed the US FDA audit. We have developed an innovative chemical process to substantially improve the yield and reduce the cost. For this process we have filed and have been granted a worldwide patent. For multiple other products the Company has received written confirmation (WC certification documents) for export into EU and we have filed and received approval for more than a dozen DMFs in Europe, US and Japan.
Future ambitions of Ausun
The Company will pay close attention to the development and trends of the international Pharmaceutical industry, optimize and integrate its existing resources, relying on its own strong R&D capabilities, develop products with technical challenges and high value, gradually carry out the production of API and formulated Drug Products, and provide a one-stop-shop for overseas large-scale pharmaceutical companies, to achieve the integrated upgrade of "pharmaceutical intermediates, APIs and formulated products" and achieve our strategic goal to become a Service Provider to Pharmaceutical companies and support them to create Medicines for Human health
According to the development strategy, the Company takes the technological innovation and international cooperation as the basic driving force for its development, implements proactive technical research, formulation and application strategies, and fully controls the development and application of pharmaceutical intermediates, APIs and formulated products, while continuously expanding the coverage of the sales network, actively exploring high-end standard markets in the United States, Japan and Europe. Ausun is striving to become a leading pharmaceutical company in China in the next 3-5 years, well recognized based on a great track-record and high quality, and finally a first-class pharmaceutical company with international recognition in China.